Absolutely agree , look at the rewards to Acadia for bringing 2 rare disease neurological drugs to market ? Today they are worth less than they were BEFORE Nuplazid passed phase 3 and got approved and BEFORE they took Trofinetide through the same costly process . They are valued at what they were in 2015 !!!
What's the point going ahead with these outcomes ?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$15.39 |
Change
0.550(3.71%) |
Mkt cap ! $1.915B | |||
| Open | High | Low | Value | Volume |
| $15.00 | $15.50 | $14.91 | $9.641M | 631.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $15.34 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.39 | 1224 | 1 |
View Market Depth
| Last trade - 16.10pm 18/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |